US 12,215,095 B2
Compounds for the treatment of respiratory diseases
Alastair Stewart, The University of Melbourne (AU); Spencer Williams, The University of Melbourne (AU); and Zalihe Hakki, The University of Melbourne (AU)
Assigned to The University of Melbourne, Melbourne (AU)
Appl. No. 17/291,707
Filed by Tianli Biotech Pty Ltd, The University of Melbourne (AU)
PCT Filed Nov. 7, 2019, PCT No. PCT/AU2019/051225
§ 371(c)(1), (2) Date May 6, 2021,
PCT Pub. No. WO2020/093098, PCT Pub. Date May 14, 2020.
Claims priority of application No. 2018904241 (AU), filed on Nov. 7, 2018; and application No. 2018904242 (AU), filed on Nov. 7, 2018.
Prior Publication US 2022/0002269 A1, Jan. 6, 2022
Int. Cl. C07D 403/04 (2006.01); A61P 11/00 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01)
CPC C07D 403/04 (2013.01) [A61P 11/00 (2018.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07B 2200/05 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A compound of formula (I) or a salt, solvate, N-oxide, tautomer, stereoisomer, polymorph and/or prodrug thereof:

OG Complex Work Unit Chemistry
wherein:
R1 is C1-3alkylC3-6cycloalkyl;
R2 is H;
R3 is selected from the group consisting of H, F, Cl and CH3;
R4 is selected from the group consisting of —C0-3alkylC3-12cycloalkyl and C1-12alkyl;
wherein each of R1 and R4 is optionally substituted.